139 related articles for article (PubMed ID: 12000825)
21. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
22. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
23. Caspofungin versus liposomal amphotericin B for empirical therapy.
Tattevin P; Bareau B; Camus C
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
[No Abstract] [Full Text] [Related]
24. [The future of antifungal agents].
Maesaki S
Rinsho Ketsueki; 2007 Jan; 48(1):26-35. PubMed ID: 17313074
[No Abstract] [Full Text] [Related]
25. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole versus amphotericin B for invasive aspergillosis.
Karthaus M
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12494937
[No Abstract] [Full Text] [Related]
27. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia.
Torres A; Serrano J; Rojas R; Martín V; Martín C; Tabares S; Molina JR; Capote M; Martínez F; Gómez P; Sánchez-García J
Eur J Haematol; 2010 Mar; 84(3):271-3. PubMed ID: 19878274
[No Abstract] [Full Text] [Related]
28. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole.
Panicker J; Walsh T; Kamani N
Pediatr Infect Dis J; 2006 Apr; 25(4):377-9. PubMed ID: 16567998
[TBL] [Abstract][Full Text] [Related]
29. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
[TBL] [Abstract][Full Text] [Related]
30. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG
Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B.
Stanzani M; Vianelli N; Bandini G; Paolini S; Arpinati M; Bonifazi F; Giannini B; Agostinelli C; Baccarani M; Ricci P
J Infect; 2006 Dec; 53(6):e243-6. PubMed ID: 16584783
[TBL] [Abstract][Full Text] [Related]
33. Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection.
Askari E; Jarque I; Nicolás Franco S; Cáceres Agra JJ
Rev Esp Quimioter; 2010 Dec; 23(4):210-2. PubMed ID: 21191561
[No Abstract] [Full Text] [Related]
34. Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection.
Ruíz-Cendoya M; Madrid H; Pastor J; Guarro J
Int J Antimicrob Agents; 2010 Feb; 35(2):152-5. PubMed ID: 20005680
[TBL] [Abstract][Full Text] [Related]
35. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
36. Voriconazole.
Med Lett Drugs Ther; 2002 Jul; 44(1135):63-5. PubMed ID: 12138377
[No Abstract] [Full Text] [Related]
37. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole.
Klont RR; Eggink CA; Rijs AJ; Wesseling P; Verweij PE
Clin Infect Dis; 2005 Jun; 40(12):e110-2. PubMed ID: 15909252
[TBL] [Abstract][Full Text] [Related]
38. The role of voriconazole in the treatment of central nervous system blastomycosis.
Ta M; Flowers SA; Rogers PD
Ann Pharmacother; 2009 Oct; 43(10):1696-700. PubMed ID: 19724015
[TBL] [Abstract][Full Text] [Related]
39. Liposomal amphotericin B for fever and neutropenia.
Winston DJ; Schiller GJ; Territo MC
N Engl J Med; 1999 Oct; 341(15):1154-5. PubMed ID: 10515755
[No Abstract] [Full Text] [Related]
40. Liposomal amphotericin B for fever and neutropenia.
Rakita R
N Engl J Med; 1999 Oct; 341(15):1153-4; author reply 1154-5. PubMed ID: 10515754
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]